Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Seoul stocks open lower on profit-taking ahead of Nvidia earnings

Seoul stocks opened lower Monday, as investors sat on the sidelines ahead of major events, including the upcoming earnings release from U.S. chip giant Nvidia. The benchmark Korea Composite Stock Price Index (KOSPI) was down 0.73 percent, or 50.77 points, at 6,862.18 in the first 1 minute of trading. After closing above 6,900 points on Friday, the index lost ground as investors locked in gains…

Seoul stocks open lower on profit-taking ahead of Nvidia earnings

Seoul stocks commenced trading on Monday on a downward trajectory, as market participants remained cautious ahead of significant events, notably the forthcoming earnings announcement from the U.S. tech behemoth Nvidia. The KOSPI, the primary benchmark index in South Korea, fell by 0.73 percent, or 50.77 points, to 6,862.18 within the first minute of trading.

This decline marked a shift from Friday's closing above 6,900 points. The index's downside momentum was attributed to investors cashing in profits from large-cap chip stocks, as they eagerly awaited the impending earnings release from Nvidia for insights into the potential trajectory of the artificial intelligence (AI) sector. Notably, major indices on Wall Street had demonstrated resilience last week, closing higher despite a surge in U.S. government bond yields, as investors sought value through bargain purchases.

The S&P 500 and the tech-focused Nasdaq both reported a modest 0.43 percent increase. Furthermore, investors are closely monitoring the forthcoming Jackson Hole meeting of the U.S. Federal Reserve and the Bank of Korea's upcoming policy decision, scheduled for this week. Market cap leaders, such as Samsung Electronics and SK hynix, exhibited contrasting performance, with the former experiencing a 5.33 percent decline and the latter rallying 2.02 percent. Hyundai Motor, the world's top car manufacturer, showed a slight gain of 0.24 percent.

Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Read the original at koreatimes.co.kr →

More in Finance & Markets

Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?

Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs.

  • Symbiotec Pharmalab raising ₹150 crore through IPO for debt repayment
  • Company specializes in APIs, nutritional ingredients, specialty products
  • Global leader in corticosteroid and steroidal-hormone APIs with 38.2% market share

More from Monday 24 August →